Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Allarity Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ALLR
Nasdaq
8731
https://allarity.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Allarity Therapeutics Inc
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
- May 14th, 2024 8:01 pm
All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy
- May 7th, 2024 4:00 pm
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
- May 7th, 2024 1:30 pm
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
- May 6th, 2024 12:00 pm
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
- May 2nd, 2024 12:00 pm
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
- Apr 29th, 2024 11:00 am
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
- Apr 17th, 2024 1:10 pm
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
- Apr 4th, 2024 1:15 pm
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
- Mar 27th, 2024 12:30 pm
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
- Mar 25th, 2024 11:30 am
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
- Mar 8th, 2024 12:15 pm
Allarity Therapeutics to Present at Biomarkers 2024
- Feb 28th, 2024 11:00 am
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
- Dec 12th, 2023 11:00 am
ALLR: Stenoparib Clinical Update
- Dec 7th, 2023 9:47 am
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
- Dec 5th, 2023 12:30 pm
Allarity Therapeutics to Present at Biomarkers Europe 2023
- Oct 2nd, 2023 11:00 am
Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology
- Sep 14th, 2023 1:25 pm
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
- Aug 30th, 2023 8:05 pm
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
- Jul 31st, 2023 10:00 am
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
- Jul 24th, 2023 10:00 am
Scroll